Focus-X Therapeutics

About:

Focus-X Therapeutics is a preclinical-stage biotechnology company focused on the radiopharmaceutical pipeline.

Top Investors: Viva BioInnovator, Xiamen Changrong Investment Management

Description:

Focus-X Therapeutics is a preclinical-stage biotechnology company focused on the radiopharmaceutical pipeline. They focus on unmet needs in cancer diagnosis and therapy by applying our theragnostic approach to solid tumors with a very low five-year survival rate. It brings its proprietary radioligand therapy (RLT) to precisely deliver alpha or beta emitters to break down cancer cell DNA.

Total Funding Amount:

$1.5M

Headquarters Location:

Sammamish, Washington, United States

Founded Date:

2020-08-14

Founders:

Fa Liu, Hui Qi

Number of Employees:

1-10

Last Funding Date:

2022-01-01

IPO Status:

Private

Industries: